EU approves Opdivo-Yervoy combo for colorectal cancer - Investing.com

Bristol Myers Squibb announces European Commission approval of Opdivo and Yervoy as first-line treatment for MSI-H/dMMR metastatic colorectal cancer, based on Phase 3 CheckMate -8HW trial results showing 79% reduction in disease progression or death risk compared to chemotherapy. The approval extends across all 27 EU member states, Iceland, Liechtenstein, and Norway.


Related News

EU approves Opdivo-Yervoy combo for colorectal cancer - Investing.com

Bristol Myers Squibb announces European Commission approval of Opdivo and Yervoy as first-line treatment for MSI-H/dMMR metastatic colorectal cancer, based on Phase 3 CheckMate -8HW trial results showing 79% reduction in disease progression or death risk compared to chemotherapy. The approval extends across all 27 EU member states, Iceland, Liechtenstein, and Norway.

© Copyright 2024. All Rights Reserved by MedPath